Chemical chaperone and inhibitor discovery: potential treatments for protein conformational diseases

Jian-Hua Zhao, Hsuan-Liang Liu, Hsin-Yi Lin, Chih-Hung Huang, Hsu-Wei Fang, Shiao-Shing Chen, Yih Ho, Wei-Bor Tsai, Wen-Yih Chen

研究成果: 雜誌貢獻文章

摘要

Protein misfolding and aggregation cause a large number of neurodegenerative diseases in humans due to (i) gain of function as observed in Alzheimer's disease, Huntington's disease, Parkinson's disease, and Prion's disease or (ii) loss of function as observed in cystic fibrosis and alpha1-antitrypsin deficiency. These misfolded proteins could either lead to the formation of harmful amyloids that become toxic for the cells or to be recognized and prematurely degraded by the protein quality control system. An increasing number of studies has indicated that some low-molecular-weight compounds named as chemical chaperones can reverse the mislocalization and/or aggregation of proteins associated with human conformational diseases. These small molecules are thought to non-selectively stabilize proteins and facilitate their folding. In this review, we summarize the probable mechanisms of protein conformational diseases in humans and the use of chemical chaperones and inhibitors as potential therapeutic agents against these diseases. Furthermore, recent advanced experimental and theoretical approaches underlying the detailed mechanisms of protein conformational changes and current structure-based drug designs towards protein conformational diseases are also discussed. It is believed that a better understanding of the mechanisms of conformational changes as well as the biological functions of these proteins will lead to the development and design of potential interfering compounds against amyloid formation associated with protein conformational diseases.
原文英語
頁(從 - 到)39-48
頁數10
期刊Perspectives in Medicinal Chemistry
1
出版狀態已發佈 - 十二月 11 2007
對外發佈Yes

指紋

Proteins
Amyloid
Prion Diseases
Poisons
Drug Design
Huntington Disease
Cystic Fibrosis
Neurodegenerative Diseases
Quality Control
Parkinson Disease
Alzheimer Disease
Molecular Weight
Therapeutics

引用此文

Chemical chaperone and inhibitor discovery : potential treatments for protein conformational diseases. / Zhao, Jian-Hua; Liu, Hsuan-Liang; Lin, Hsin-Yi; Huang, Chih-Hung; Fang, Hsu-Wei; Chen, Shiao-Shing; Ho, Yih; Tsai, Wei-Bor; Chen, Wen-Yih.

於: Perspectives in Medicinal Chemistry, 卷 1, 11.12.2007, p. 39-48.

研究成果: 雜誌貢獻文章

Zhao, J-H, Liu, H-L, Lin, H-Y, Huang, C-H, Fang, H-W, Chen, S-S, Ho, Y, Tsai, W-B & Chen, W-Y 2007, 'Chemical chaperone and inhibitor discovery: potential treatments for protein conformational diseases', Perspectives in Medicinal Chemistry, 卷 1, 頁 39-48.
Zhao, Jian-Hua ; Liu, Hsuan-Liang ; Lin, Hsin-Yi ; Huang, Chih-Hung ; Fang, Hsu-Wei ; Chen, Shiao-Shing ; Ho, Yih ; Tsai, Wei-Bor ; Chen, Wen-Yih. / Chemical chaperone and inhibitor discovery : potential treatments for protein conformational diseases. 於: Perspectives in Medicinal Chemistry. 2007 ; 卷 1. 頁 39-48.
@article{d915123de8d54af1a9d6f88c1a35c866,
title = "Chemical chaperone and inhibitor discovery: potential treatments for protein conformational diseases",
abstract = "Protein misfolding and aggregation cause a large number of neurodegenerative diseases in humans due to (i) gain of function as observed in Alzheimer's disease, Huntington's disease, Parkinson's disease, and Prion's disease or (ii) loss of function as observed in cystic fibrosis and alpha1-antitrypsin deficiency. These misfolded proteins could either lead to the formation of harmful amyloids that become toxic for the cells or to be recognized and prematurely degraded by the protein quality control system. An increasing number of studies has indicated that some low-molecular-weight compounds named as chemical chaperones can reverse the mislocalization and/or aggregation of proteins associated with human conformational diseases. These small molecules are thought to non-selectively stabilize proteins and facilitate their folding. In this review, we summarize the probable mechanisms of protein conformational diseases in humans and the use of chemical chaperones and inhibitors as potential therapeutic agents against these diseases. Furthermore, recent advanced experimental and theoretical approaches underlying the detailed mechanisms of protein conformational changes and current structure-based drug designs towards protein conformational diseases are also discussed. It is believed that a better understanding of the mechanisms of conformational changes as well as the biological functions of these proteins will lead to the development and design of potential interfering compounds against amyloid formation associated with protein conformational diseases.",
author = "Jian-Hua Zhao and Hsuan-Liang Liu and Hsin-Yi Lin and Chih-Hung Huang and Hsu-Wei Fang and Shiao-Shing Chen and Yih Ho and Wei-Bor Tsai and Wen-Yih Chen",
year = "2007",
month = "12",
day = "11",
language = "English",
volume = "1",
pages = "39--48",
journal = "Perspectives in Medicinal Chemistry",
issn = "1177-3910",
publisher = "Libertas Academica Ltd.",

}

TY - JOUR

T1 - Chemical chaperone and inhibitor discovery

T2 - potential treatments for protein conformational diseases

AU - Zhao, Jian-Hua

AU - Liu, Hsuan-Liang

AU - Lin, Hsin-Yi

AU - Huang, Chih-Hung

AU - Fang, Hsu-Wei

AU - Chen, Shiao-Shing

AU - Ho, Yih

AU - Tsai, Wei-Bor

AU - Chen, Wen-Yih

PY - 2007/12/11

Y1 - 2007/12/11

N2 - Protein misfolding and aggregation cause a large number of neurodegenerative diseases in humans due to (i) gain of function as observed in Alzheimer's disease, Huntington's disease, Parkinson's disease, and Prion's disease or (ii) loss of function as observed in cystic fibrosis and alpha1-antitrypsin deficiency. These misfolded proteins could either lead to the formation of harmful amyloids that become toxic for the cells or to be recognized and prematurely degraded by the protein quality control system. An increasing number of studies has indicated that some low-molecular-weight compounds named as chemical chaperones can reverse the mislocalization and/or aggregation of proteins associated with human conformational diseases. These small molecules are thought to non-selectively stabilize proteins and facilitate their folding. In this review, we summarize the probable mechanisms of protein conformational diseases in humans and the use of chemical chaperones and inhibitors as potential therapeutic agents against these diseases. Furthermore, recent advanced experimental and theoretical approaches underlying the detailed mechanisms of protein conformational changes and current structure-based drug designs towards protein conformational diseases are also discussed. It is believed that a better understanding of the mechanisms of conformational changes as well as the biological functions of these proteins will lead to the development and design of potential interfering compounds against amyloid formation associated with protein conformational diseases.

AB - Protein misfolding and aggregation cause a large number of neurodegenerative diseases in humans due to (i) gain of function as observed in Alzheimer's disease, Huntington's disease, Parkinson's disease, and Prion's disease or (ii) loss of function as observed in cystic fibrosis and alpha1-antitrypsin deficiency. These misfolded proteins could either lead to the formation of harmful amyloids that become toxic for the cells or to be recognized and prematurely degraded by the protein quality control system. An increasing number of studies has indicated that some low-molecular-weight compounds named as chemical chaperones can reverse the mislocalization and/or aggregation of proteins associated with human conformational diseases. These small molecules are thought to non-selectively stabilize proteins and facilitate their folding. In this review, we summarize the probable mechanisms of protein conformational diseases in humans and the use of chemical chaperones and inhibitors as potential therapeutic agents against these diseases. Furthermore, recent advanced experimental and theoretical approaches underlying the detailed mechanisms of protein conformational changes and current structure-based drug designs towards protein conformational diseases are also discussed. It is believed that a better understanding of the mechanisms of conformational changes as well as the biological functions of these proteins will lead to the development and design of potential interfering compounds against amyloid formation associated with protein conformational diseases.

M3 - Article

C2 - 19812735

VL - 1

SP - 39

EP - 48

JO - Perspectives in Medicinal Chemistry

JF - Perspectives in Medicinal Chemistry

SN - 1177-3910

ER -